St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced new results from the EnligHTN I study, confirming safe, rapid and sustained reduction in blood pressure measurements a year and a half post-procedure. Data presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, indicates that patients with drug-resistant hypertension treated with the EnligHTN™ Multi-Electrode Renal Denervation System averaged a 24 mmHg (millimeters of mercury) reduction in systolic blood pressure as measured in an office setting.
Help employers find you! Check out all the jobs and post your resume.
